Table 2 The details of pooled ORR and DCR

ORR for ICIs-based therapy

8.5 (4.4–13.5)

38

84.5 (79.7–88.2)

 < 0.01

Random effect

z = 0.9, p-value = 0.39

ORR for ICIs-based therapy as first-line

74.2 (61.4–85.4)

3

48.5 (0.0–85.0)

0.14

Fixed effect

z = -1.6, p-value = 0.12

ORR for ICIs-based therapy as second-line or beyond

6.4 (3.3–10.4)

28

66.7 (50.5–77.6)

 < 0.01

Random effect

z = -0.4, p-value = 0.71

ORR-anti-CTLA-4 + anti-PD-(L)1 + radiotherapy

9.0 (0.9–21.9)

2

43.8

0.18

Fixed effect

/

ORR-anti-PD-(L)1 + anti-VEGF + chemotherapy

42.4 (10.0–78.6)

5

94.4 (89.8–97.0)

 < 0.01

Random effect

z = 0.5, p-value = 0.62

ORR-anti-PD-(L)1 + anti-VEGF + chemotherapy (first-line)

74.2 (61.4–85.4)

3

48.5 (0.0–85.0)

0.14

Fixed effect

z = -1.6, p-value = 0.12

ORR-anti-PD-(L)1 + anti-VEGF + chemotherapy (second-line or beyond)

9.5 (4.0–16.7)

2

0.0

0.96

Fixed effect

/

ORR-anti-PD-(L)1 + anti-EGFR + chemotherapy

9.5 (0.0–53.2)

2

80.3 (15.3–95.4)

0.02

Random effect

/

ORR-anti-PD-(L)1 + TKIs

6.1 (1.7–12.4)

12

69.3 (44.3–83.1)

 < 0.01

Random effect

z = 0.2, p-value = 0.87

ORR-anti-PD-(L)1 + chemotherapy

4.3 (0.6–10.1)

5

27.4 (0.0–71.4)

0.24

Fixed effect

z = -0.3, p-value = 0.79

ORR-anti-PD-(L)1 monotherapy

2.7 (0.0–9.4)

3

66.6 (0.0–90.4)

0.05

Random effect

z = -0.5, p-value = 0.60

DCR for ICIs-based therapy

48.2 (37.8–58.6)

31

87.9 (83.9–90.9)

 < 0.01

Random effect

z = -1.2, p-value = 0.23

DCR for ICIs-based therapy as first-line

98.7 (92.0–100.0)

2

18.2

0.27

Fixed effect

/

DCR for ICIs-based therapy as second-line or beyond

45.1 (34.4–56.0)

26

84.8 (78.8–89.1)

 < 0.01

Random effect

z = -1.4, p-value = 0.16

DCR-anti-CTLA-4 + anti-PD-(L)1 + radiotherapy

14.9 (0.0–63.6)

2

85.7 (42.7–96.4)

 < 0.01

Random effect

/

DCR-anti-PD-(L)1 + anti-VEGF + chemotherapy

92.0 (68.3–100.0)

3

83.7 (51.0–94.6)

 < 0.01

Random effect

z = -0.5, p-value = 0.60

DCR-anti-PD-(L)1 + anti-VEGF + chemotherapy (first-line)

98.7 (92.0–100.0)

2

18.2

0.27

Fixed effect

/

DCR-anti-PD-(L)1 + anti-VEGF + chemotherapy (second-line or beyond)

69.6 (49.0–87.0)

1

/

/

/

/

DCR-anti-PD-(L)1 + anti-EGFR + chemotherapy

60.9 (39.3–80.7)

2

0.0

0.94

Fixed effect

/

DCR-anti-PD-(L)1 + TKIs

59.8 (49.4–69.6)

11

66.9 (37.7–82.5)

 < 0.01

Random effect

z = -0.5, p-value = 0.64

DCR-anti-PD-(L)1 + chemotherapy

39.5 (12.4–70.2)

4

84.9 (62.4–93.9)

 < 0.01

Random effect

z = 1.8, p-value = 0.07

DCR-anti-PD-(L)1 monotherapy

25.1 (17.3–33.7)

2

0.0

0.70

Fixed effect

/